Javascript must be enabled to continue!
Morphologic brain network predicts levodopa responsiveness in Parkinson disease
View through CrossRef
BackgroundThe levodopa challenge test (LCT) has been routinely used in Parkinson disease (PD) evaluation and predicts the outcome of deep brain stimulation (DBS). Guidelines recommend that patients with an improvement in Unified Parkinson’s Disease Rating Scale (UPDRS)-III score > 33% in the LCT receive DBS treatment. However, LCT results are affected by many factors, and only provide information on the immediate effectiveness of dopamine. The aim of the present study was to investigate the relationship between LCT outcome and brain imaging features of PD patients to determine whether the latter can be used to identify candidates for DBS.MethodsA total of 38 PD patients were enrolled in the study. Based on improvement in UPDRS-III score in the LCT, patients were divided into low improvement (PD-LCT-L) and high improvement (PD-LCT-H) groups. Each patient’s neural network was reconstructed based on T1-weighted magnetic resonance imaging data using the Jensen–Shannon divergence similarity estimation method. The network was established with the multiple kernel support vector machine technique. We analyzed differences in individual morphologic brain networks and their global and local metrics to determine whether there were differences in the connectomes of PD-LCT-L and PD-LCT-H groups.ResultsThe 2 groups were similar in terms of demographic and clinical characteristics. Mean ± SD levodopa responsiveness was 26.52% ± 3.47% in the PD-LCT-L group (N = 13) and 58.66% ± 4.09% in the PD-LCT-H group (N = 25). There were no significant differences between groups in global and local metrics. There were 43 consensus connections that were affected in both groups; in PD-LCT-L patients, most of these connections were decreased whereas those related to the dorsolateral superior frontal gyrus and left cuneus were significantly increased.ConclusionMorphologic brain network assessment is a valuable method for predicting levodopa responsiveness in PD patients, which can facilitate the selection of candidates for DBS.
Frontiers Media SA
Title: Morphologic brain network predicts levodopa responsiveness in Parkinson disease
Description:
BackgroundThe levodopa challenge test (LCT) has been routinely used in Parkinson disease (PD) evaluation and predicts the outcome of deep brain stimulation (DBS).
Guidelines recommend that patients with an improvement in Unified Parkinson’s Disease Rating Scale (UPDRS)-III score > 33% in the LCT receive DBS treatment.
However, LCT results are affected by many factors, and only provide information on the immediate effectiveness of dopamine.
The aim of the present study was to investigate the relationship between LCT outcome and brain imaging features of PD patients to determine whether the latter can be used to identify candidates for DBS.
MethodsA total of 38 PD patients were enrolled in the study.
Based on improvement in UPDRS-III score in the LCT, patients were divided into low improvement (PD-LCT-L) and high improvement (PD-LCT-H) groups.
Each patient’s neural network was reconstructed based on T1-weighted magnetic resonance imaging data using the Jensen–Shannon divergence similarity estimation method.
The network was established with the multiple kernel support vector machine technique.
We analyzed differences in individual morphologic brain networks and their global and local metrics to determine whether there were differences in the connectomes of PD-LCT-L and PD-LCT-H groups.
ResultsThe 2 groups were similar in terms of demographic and clinical characteristics.
Mean ± SD levodopa responsiveness was 26.
52% ± 3.
47% in the PD-LCT-L group (N = 13) and 58.
66% ± 4.
09% in the PD-LCT-H group (N = 25).
There were no significant differences between groups in global and local metrics.
There were 43 consensus connections that were affected in both groups; in PD-LCT-L patients, most of these connections were decreased whereas those related to the dorsolateral superior frontal gyrus and left cuneus were significantly increased.
ConclusionMorphologic brain network assessment is a valuable method for predicting levodopa responsiveness in PD patients, which can facilitate the selection of candidates for DBS.
Related Results
Brain Organoids, the Path Forward?
Brain Organoids, the Path Forward?
Photo by Maxim Berg on Unsplash
INTRODUCTION
The brain is one of the most foundational parts of being human, and we are still learning about what makes humans unique. Advancements ...
Plasma Concentration of Levodopa in Patients with Parkinson’s Disease
Plasma Concentration of Levodopa in Patients with Parkinson’s Disease
Responses in plasma concentration of levodopa to administration of levodopa alone or combined with the extracerebral decarboxylase inhibitor, Ro 4-4602, were studied in 173 parkins...
Modulatory Effect of Levodopa on the Basal Ganglia-Cerebellum Connectivity in Parkinson’s Disease
Modulatory Effect of Levodopa on the Basal Ganglia-Cerebellum Connectivity in Parkinson’s Disease
Abstract
Levodopa has remained the mainstay of medical therapy for Parkinson’s disease since its development in the 1980s. However, long-term medication use is asso...
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia
AbstractBackgroundLevodopa‐induced dyskinesias are an often debilitating side effect of levodopa therapy in Parkinson's disease. Although up to 90% of individuals with PD develop t...
Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug‐induced chorea
Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug‐induced chorea
AbstractWe studied the temporal patterns of chorea and plasma levodopa profiles in 30 patients with Parkinson's disease whose motor fluctuations were difficult to characterize and ...
Levodopa impairs lysosomal function in sensory neurons in vitro
Levodopa impairs lysosomal function in sensory neurons in vitro
Abstract
Parkinson’s disease (PD) is the second-most common neurodegenerative disease world-wide. Patients are diagnosed based upon movement disorders, including br...
[RETRACTED] Gro-X Brain Reviews - Is Gro-X Brain A Scam? v1
[RETRACTED] Gro-X Brain Reviews - Is Gro-X Brain A Scam? v1
[RETRACTED]➢Item Name - Gro-X Brain➢ Creation - Natural Organic Compound➢ Incidental Effects - NA➢ Accessibility - Online➢ Rating - ⭐⭐⭐⭐⭐➢ Click Here To Visit - Official Website - ...
Impact of a public health policy on accessibility to levodopa for people with Parkinson’s disease in Brazil
Impact of a public health policy on accessibility to levodopa for people with Parkinson’s disease in Brazil
Abstract
Background
Access to levodopa remains limited in many low- and middle-income countries. Brazil’s Popular Pharmacy Prog...

